-
2022-502503-30-00
5
2022-12-15
Acute lymphoblastic leukemia
-
2022-503012-16-00
5
2022-07-20
Patients on treatment with Factor Xa Inhibitor needing for an urgent i
-
2022-502425-18-00
5
2022-04-19
Adenocarcinoma of the prostate
-
2024-511686-11-00
5
2021-10-05
Multiple Sclerosis in pediatric patients
-
2023-506581-31-00
1
2021-06-15
Acute Leukemia
-
2023-506838-68-00
9
2020-12-10
Renal cell carcinoma
-
2024-516215-24-00
4
2026-07-01
TAkayasu ARteritiS
-
2025-524367-20-00
4
2026-06-30
Adult patients with primary mitochondrial disease
-
2025-523481-24-00
5
2026-06-24
Participants with Progressive Supranuclear Palsy Richardson Syndrome (
-
2025-522138-29-00
4
2026-06-18
Philadelphia positive Chronic Myeloid leukemia in Chronic Phase with n
-
2024-513292-40-00
5
2026-06-15
Multiple sclerosis
-
2024-519246-75-01
4
2026-06-15
Patients With Muscle-Invasive Bladder Cancer
-
2025-522193-37-00
5
2026-06-09
Septic arthritis
-
2025-524160-38-00
5
2026-05-12
Renal Cell Carcinoma, hepatocellular carcinoma, nonMSI-H/dMMR colorect
-
2024-520205-39-00
5
2026-04-21
Traumatic brain injury
-
2025-521546-23-00
5
2026-04-21
Secondary progressive multiple sclerosis
-
2024-516639-28-00
5
2026-03-27
norepinephrine-refractory vasoplegic shock
-
2023-504957-11-00
5
2026-03-24
Metastatic castration resistant prostate cancer
-
2024-519444-33-00
5
2026-03-12
HER2-expressing endometrial cancer (IHC 3+/2+)
-
2025-521636-10-00
4
2026-02-04
Progressive Forms of Multiple Sclerosis (PMS)
-
2023-508930-33-00
4
2026-01-30
Non-infectious active cryoglobulinemia vasculitis who are either refra
-
2025-522400-24-00
10
2026-01-27
Metastatic urothelial cancer
-
2024-514400-14-00
4
2026-01-23
liver transplanted patients with advanced hepatocellular carcinoma
-
2024-515023-11-00
5
2026-01-22
Advanced Clear Cell Renal Cell Carcinoma